Advertisement

Zusammenfassung

Durch Degeneration dopaminerger Neurone der Substantia nigra kommt es zu einer Dopaminverarmung im Striatum. Dieses wurde in den frühen 60er Jahren als wesentliche Ursache für die motorischen Defizite des Parkinsonsyndroms erkannt (Ehringer und Hornykiewicz 1960). Seither ist die Therapie stark auf die Substitution dieses Dopamindefizits ausgerichtet, obgleich bekanntermaßen auch andere Transmittersysteme für die motorischen Störungen des Parkinsonpatienten verantwortlich sind. Da Dopamin die Blut-Hirnschranke nicht passieren kann, wurde die Substitution mit der Vorläufersubstanz L-Dopa durchgeführt (Birkmayer und Hornykiewicz 1961). Nach Resorption und Passage ins Gehirn wird L-Dopa intraneuronal zu Dopamin umgebaut und in den synaptischen Vesikeln gespeichert. Peroral appliziertes L-Dopa wird zu 90% in der Peripherie zu Dopamin dekarboxyliert, so daß nur ein Bruchteil des eingenommenen L-Dopa das Gehirn wirklich erreicht und systemische Nebenwirkungen wie Nausea, Erbrechen oder Kreislaufdysregulation auftreten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Axelrod J, Senoh S, Witkop B (1958a) O-methyl-ation of catecholamines in vivo. J Biol Chem 233: 697–701PubMedGoogle Scholar
  2. Axelrod J, Tomchick R (1958b) Enzymatic O-methylation of ephedrine and other catechols. J Biol Chem 233: 702–705PubMedGoogle Scholar
  3. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G et al. (1997) COMT inhibition with tolcapone reduces the „wear-ing-off“ phenomenon and levodopa requirements in fluctuating parkinsonian patients. JNNP 63: 421–428Google Scholar
  4. Benson R, Crowell B, Hill B, Doonquah K, Charlton C (1993) The effects of L-dopa on the activity of methionineadenosyl-transferase: relevance to L-dopa therapy and tolerance. Neurochem Res 18: 325–330PubMedCrossRefGoogle Scholar
  5. Birkmayer W (1969) Experimentelle Ergebnisse über die Kombinationsbehandlung des Par-kinson-Syndroms mit L-Dopa und einem Dekarboxylasehemmer. Wien Klin Wochen-schr 81: 677–679Google Scholar
  6. Birkmayer W, Hornykiewicz O (1961) Der L-3,4-Dihydroxyphenylalanin (= DOPA)-Effekt bei der Parkinson Akinese. Wien Klin Wochen-schr 73: 787–788Google Scholar
  7. Birkmayer W, Mentasti M (1967) Weitere experimentelle Untersuchungen über den Katecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson-und Choreasyndrom). Arch Psych Z ges Neurol 210: 29–35CrossRefGoogle Scholar
  8. Bottiglieri T, Godfrey P, Flynn T, Carney MWP, Tone BK, Reynolds EH (1990) Cerebrospinal S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. JNNP 53: 1096–1098Google Scholar
  9. Colzi A, Zürcher G, Kettler R, Da Prada M (1992) L-Dopa. Einleitung, Pharmakologie, Neuro-biochemie, Wirkungsmechanismus. In: Riede-Rer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5. Springer, Wien New York, S 29–41Google Scholar
  10. Davis TL, Roznoski M, Bruns RS (1995) Effects of tolcapone in Parkinson’s patients taking L-di-hydroxyphenylalanine/carbidopa and selege-line. Mov Disord 10: 349–351PubMedCrossRefGoogle Scholar
  11. Dupont E, Burgunder J-M, Findley LJ, Olsson J-E, Dorflinger E et al. (1997) Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 12: 928–934PubMedCrossRefGoogle Scholar
  12. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239PubMedCrossRefGoogle Scholar
  13. Friedgen B, Wölfel R, Graefe K-H (1996) The contribution of monoamine oxidase and cat-echol-O-methyltransferase to the total-body and pulmonary plasma clearence of catecholamines. Naunyn Schmiedebergers Arch Pharmacol 353: 193–199Google Scholar
  14. Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27: 135–206PubMedGoogle Scholar
  15. Illi A, Sundberg S, Koulu M et al. (1994) COMT inhibition by high dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 32: 582–588PubMedGoogle Scholar
  16. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 58: 221–227PubMedCrossRefGoogle Scholar
  17. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A (1996) Simultaneous inhibition of catechol-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 51: 273–276PubMedCrossRefGoogle Scholar
  18. Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G, Aitken J (1997a) The effect of COMT inhibition by Tolcapone on tolerability and pharmacokinetics of different levodopa/bens-erazide formulations. Eur Neurol 38: 59–67PubMedCrossRefGoogle Scholar
  19. Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW (1997b) Optimizing levodopa pharmacokinetics with multiple tolcapone doses in elderly. Clin Pharmacol Ther 62: 300–310PubMedCrossRefGoogle Scholar
  20. Kaakkola S, Wurtmann RJ (1992) Effects of COMT inhibitors on striatal dopamin metabolism: a microdialysis study. Brain Res 587: 241–249PubMedCrossRefGoogle Scholar
  21. Kaakkola S, Wurtmann RJ (1993) Effects of cate-chol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137–144PubMedCrossRefGoogle Scholar
  22. Kaakkola S, Gordin A, Männistö PT (1994a) General properties and clinical possibilities of new selective inhibitors of catechol-O-meth-yltransferase. Gen Pharmac 25: 813–824CrossRefGoogle Scholar
  23. Kaakkola S, Teräviäinen H, Ahtila S, Rita H, Gordin A (1994b) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 7–80CrossRefGoogle Scholar
  24. Kaakkola S, Teravainen H, Ahtila S (1995) Entacapone in combination with standard or con-trolled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson’s disease. Eur J Neurol 2: 341–347CrossRefGoogle Scholar
  25. Keränen T, Gordin A, Harjola V-P, Karlsson M, Korpela M, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of Levodopa in healthy volunteers. Clin Neuro-pharmacol 16: 145–156Google Scholar
  26. Kurth MC, Adler CH, Hilaire MST, Singer C, Waters C, Le Witt P, Chernik DA, Dorflinger EE, Yoo K, The Tolcapone Fluctuator Study Group I (1997) Tolcapone improves motor fluctuation and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trail. Neurology 48: 81–87PubMedCrossRefGoogle Scholar
  27. Limousin P, Pollak P, Pfefen JP, Tournier-Gerva-Son CL, Dubuis R, Perret JE (1995) Acute administration of Levodopa-Benserazide and Tolcapone, a COMT inhibitor, in Parkinson’s disease. Clin Neuropharmacol 18: 258–265PubMedCrossRefGoogle Scholar
  28. Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson’s disease? Trends Pharmacol Sci 10: 54–56PubMedCrossRefGoogle Scholar
  29. Männistö PT, Tuomainen P, Tuominen RK (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in rats. Br J Pharmacol 105: 569–574PubMedCrossRefGoogle Scholar
  30. Mcneely W, Davis R (1997) Entacapone. CNS Drugs 8: 79–88CrossRefGoogle Scholar
  31. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripheral acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease. JNNP 57: 186–189Google Scholar
  32. Myllylä VV, Jackson M, Larsen JP, Baas H for Tips group I (1997) Efficacy and safety of tolcapone in levodopa-treated Parkinson’s disease patients with „wearing off“ phenomenon: a multicentre, double-blind, randomized, placebo-controlled trail. Eur J Neurol 4: 333–341CrossRefGoogle Scholar
  33. Müller T, Kuhn W, Przuntek H (1993) Therapy with central active catechol-O-methyltrans-ferase (COMT) inhibitors: is addition of monoamine oxidase (MAO)-inhibitor necessary to slow progress of neurodegenerative disorders? J Neural Transm 92: 187–195CrossRefGoogle Scholar
  34. Nissinen E, Touminen R, Perhoniemi V, Kaakkola S (1988) Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci 42: 2609–2614PubMedCrossRefGoogle Scholar
  35. Nutt JG (1996) Effects of Catechol-O-Methly-transferase (COMT) inhibitors on pharmacokinetics of L-Dopa. Adv Neurol 69: 493–496PubMedGoogle Scholar
  36. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21: 584–588PubMedCrossRefGoogle Scholar
  37. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammer-Stad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on pharmacokinetics and pharmacodynamics of levodopa in Parkinsonian patients. Neurology 44: 913–919PubMedCrossRefGoogle Scholar
  38. Parkinson Study Group (1997) Entacapone improves motor fluctuation in Levodopa-treated Parkinson’s disease patients. Ann Neurol 42: 747–755CrossRefGoogle Scholar
  39. Rajput AH, Martin W, Saint-Hilaire MH, Dorflin-Ger E, Pedder S (1997) Tolcapone improves motor fluctuation in parkinsonian patients with the „wearing-off“ phenomena: a double blind, placebo-controlled, multicenter trial. Neurology 49: 1066–1071PubMedCrossRefGoogle Scholar
  40. Ruottinen HM, Rinne UK (1996a) Entacapone prolongs levodopa response in one month double blind study in Parkinsonian patients with levodopa related fluctuations. JNNP 60: 36–40Google Scholar
  41. Ruottinen HM, Rinne UK (1996b) Effect of one month’s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacocinetics and motor response to levodopa in advanced Parkinsonian patients. Clin Neuropharmacol 19: 222–233PubMedCrossRefGoogle Scholar
  42. Routtinen HM, Rinne UK (1996c) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol 19: 283–296CrossRefGoogle Scholar
  43. Salwe GV, Brun DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ (1994) The effect of entacapone (OR-611) on brain [(18)F]-6-L-flurodopa metabolism: implication for levodopa therapy of Parkinson’s disease. Neurology 44: 1292–1297CrossRefGoogle Scholar
  44. Tasmar (1997) Product monograph. RocheGoogle Scholar
  45. Törnwall M, Männistö PT (1991) Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic transmission. Pharmacol Toxicol 69: 64–70PubMedCrossRefGoogle Scholar
  46. Waters CH, Kurth M, Bailey P, Shulman L, Le Witt P, Dorflinger E, Deptula D, Pedder S (1997) Tolcapone in stable Parkinson’s disease: efficiency and safety of long-term treatment. Neurology 49: 665–671PubMedCrossRefGoogle Scholar
  47. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti KP, Eigenmann R, Da Prada M (1990) Ro 40-7592, a novel, very potent, and oral active inhibitor of catechol-O-methlytrans-ferase: a pharmacological study in rats. Adv Neurol 53: 497–503PubMedGoogle Scholar
  48. Zürcher G, Dingemanse J, Da Prada M (1991) Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G (eds) New developments in therapy of Parkinson’s disease. John Libeey, Rome, pp 37–43Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • G. Becker
  • M. Naumann

There are no affiliations available

Personalised recommendations